The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has published a final assessment report on nitrosamine impurities.The report calls on the pharmaceutical manufacturers concerned to reduce the presence of nitrosamines in medicinal products as far as possible and to comply with the defined limits.We prepared an overview for you that summarizes the recommendations of the comprehensive 90-page report of the EMA:<ul> <li>The presence of N-nitrosamines in medicinal products for human use should be reduced as far as possible, based on the limits of the principles stated in ICH M7 (R1) and calculated considering a lifetime daily exposure. </li> <li>The risk of presence of nitrosamines should be evaluated by marketing authorisation holders respectively applicants. If there is a risk, further confirmatory tests should be performed. For new applications for authorisation, a risk assessment on the presence of nitrosamines must be submitted with the application. </li> <li>The risk assessment should include manufacturing processes of active substances and finished products, taking into account the root-causes, and subsequent confirmatory tests on the finished product, if a risk exists. </li> <li>For biological medicinal products the general risk of nitrosamine formation is very low, but the following cases should be considered: Biological medicinal products containing chemically synthesised fragments where risk factors similar to chemically synthesised active substances exist, biological medicinal products to which nitrosating reagents are deliberately added during the manufacturing process, biological medicinal products packaged in primary packaging such as blisters made of nitrocellulose </li> <li>If more than one nitrosamine has been found in a finished product or the active substance, it must be ensured that the total risk of the sum does not exceed 1:100,000 at life-time risk. Alternatively, the sum of all N-nitrosamines found should not exceed the limit for the most potent nitrosamine. </li> <li>If the limit value for a single nitrosamine cannot be met according to ICH M7 (R1), the marketing authorisation holder should immediately submit an investigation report including the potential/identified causes, preventive/corrective measures and a discussion of the impact on the risk-benefit balance. The authorities decide on a case-by-case basis. </li> <li>Exceptions to the limit values apply to finished products for the treatment of advanced cancer stages (here ICH Q3 A(R2), ICH Q3B(R2) and Q&amp;A to ICH S9 apply) or in cases where the active substance itself is genotoxic (here limits for non-mutagenic impurities according to ICH M7 (R1) can be used). </li> <li>If there are sufficient data on carcinogenicity from animal studies for a reliable TD50 value, a substance-specific limit should be derived from this. </li> <li>If N-nitrosamines are found for which no substance-specific data are available, the class-specific TTC of 18 ng/d from the Lhasa carcinogenic potency database should be used. </li> </ul>Marketing authorisation holders are obliged to carry out risk assessments for APIs as well as for the finished product, to ensure that the medicinal products are manufactured in accordance with the latest scientific and technical standards in accordance with Article 23 and Annex I of Directive 2001/83/EC and Article 16 of Directive (EC) 726/2004 and, where necessary, to adapt the manufacturing processes accordingly.It must also be ensured that all active substances and excipients are manufactured in accordance with the principles of good manufacturing practice as laid down in Article 46(f) of Directive 2001/83/EC.Further detailed information for pharmaceutical companies can be found on the <a href="https://www.ema.europa.eu/en/human-regulatory/post-authorisation/referral-procedures/nitrosamine-impurities">Nitrosamine website of the EMA</a>.Source:EMA: <a href="https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf">CHMP assessment report</a>

Regulatory

Quality

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has published a final assessment report on nitrosamine impurities.
The report calls on the pharmaceutical manufacturers concerned to reduce the presence of nitrosamines in medicinal products as far as possible and to comply with the defined limits.
We...

EMA: Final Assessment Report on Nitrosamines

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
FDA Director Martin Makary announced on May 6, 2025 that he has appointed Dr. Vinay Prasad, MD, MPH as the director of FDA’s Center for Biologics Evaluation and Research. Prasad is a hemat

New CBER Director Appointed

Xellia Pharmaceuticals, the largest and last maker of key antibiotics APIs in Europe, will shutter its Copenhagen production facility in a move seen as a blow to EU reshoring efforts.
The Danish drugmaker plans to slowly unwind operations at the facility over the next decade and move its anti-infective production “outside of Denmark,” the company s

Xellia to shutter Copenhagen antibiotics plant, dealing a blow to EU reshoring efforts

Bain Capital’s Real Estate team and Botanic Properties, a real estate investment and development firm focused on addressing the needs of the biomanufacturing industry, have acquired 45 Crosby Drive in Bedford, Massachusetts, to transform the property into an approximately 154,000-square-foot Class A biomanufacturing facility designed to meet the sp

Bain Capital & Botanic Properties Buy Massachusetts Property for Biomanufacturing Conversion

2025 marks the 12th year of the 10-year implementation of the Drug Supply Chain Security Act (DSCSA) requirements for enhanced drug traceability. At first blush, that may appear to be a missed deadline, but, in reality, it’s a necessary recognition of the complexity of pharmaceutical traceability across a vast, diverse supply chain. Tremendous prog

From Preparation To Compliance: DSCSA Implementation Takes Big Steps In 2025

Package Design
Patient-Friendly Oral Dose Packaging
Sanner GmbH
Sanner's TabTec CR features a child-resistant design with integrated desiccant technology to improve product stability and packaging efficiency while offering brand differentiation.
Package Development
Packaging Recycling Summit 2025: Charting a Circular Future
The third annual Packagi

Package Development

Wednesday, May 07, 2025
Adcentrx Therapeutics has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its investigational therapy, ADRX-0706.
ADRX-0706 is a proprietary ADC created by Adcentrx using its i-Conjugation® technology platform. It combines a fully human IgG1 antibody that targets Nectin-4 with a tubulin

Adcentrx Therapeutics Receives FDA Fast Track Designation for Nectin-4 ADC in Advanced Cervical Cancer

The multi-billion-pound deal provides a boost to the UK’s economy, however it lacks provision to aid the country’s growth ambitions, states the ABPI.
The UK and India have agreed a major trade deal, however it does not provide sufficient support the UK pharmaceutical industry, according to the Association of the British Pharmaceutical Industry (ABP

Landmark UK-India trade deal insufficient for life sciences, says industry body

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.
Key Takeaways
Vinay Prasad will replace Peter Marks as head of CBER and could limit the FDA's use of regulatory flexibility, particularl

Tougher Approval Standards May Follow Vinay Prasad's Appointment To Lead US FDA's CBER

Event summary
As part of the published Methodology Working Party 2025-2027 workplan and the Accelerating Clinical Trials in the EU (ACT EU) multi-annual workplan 2025-2026, a workshop on the use of Bayesian statistics in clinical development will be held on 17 June 2025 at EMA premises in Amsterdam.
The workshop aims to engage all stakeholders, inc

Workshop on the use of Bayesian statistics in clinical development

A Singaporen biotech company developing treatments for cardiomyopathies driven by aberrant mechanobiology.
In April 2025, Nuevocor announced the clsing of a $45 million Series B financing round to support the clinical development of its lead gene therapy for cardiomyopathy. The round was led by EVX Ventures and Boehringer Ingelheim Venture Fund, wi

Nuevocor

Latest News
New CBER Director Appointed
By Susan Haigney
FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025
Strategies for Mitigating Nitrosamine Risk
By Susan Haigney
May 7th 2025

Quality Systems

SCHOTT Poonawalla produces cartridges, vials, ampoules, and prefillable syringes. Image courtesy of SCHOTT Pharma
TPG, a global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in SCHOTT Pharma’s joint venture SCHOTT Poonawalla from Serum Institute of India (SII).
SCHOTT Poonawalla is a joint venture of

TPG Agrees to Acquire a 35% Stake in SCHOTT Poonawalla

While contract sterilizers hold the most responsibility to comply with EPA sterilization cycle requirements, MDMs play an important role in reducing gas exposure, says Wendy Mach, Packaging and Sterilization Expert at Canyon Labs.
May 7, 2025
Watch the full interview at Healthcare Packaging for more insights on medical device sterilization cycles a

Why Med Device Manufacturers Shouldn't Ignore Sterilization Cycles

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.
Key Takeaways
Pharma industry trade groups said in comments for a federal 232 investigation that the Trump Administration should adopt incentives, rather than t

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

Unlock the full potential of poorly soluble compounds with Spray Dried Dispersions (SDDs). This webinar will explore key relationships between molecular properties, formulation strategies, and manufacturing performance—covering everything from in vitro testing and physical stability to critical spray drying and tableting parameters.
Topics include:

Spray Dried Dispersions: Performance, Manufacturing and Stability

Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.
Key Takeaways
Brazilian authorities will update the country’s medicine pricing framework to bring it up to date with advances in drug technology.
A draft resoluti

Brazil To Upgrade Pricing Framework To Keep Up With Market Developments

Israel’s Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2025.
First-quarter 2025 revenues of $3.9 billion saw an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%, versus the consensus estimate of $3.98 billion.
On a non-generally accepted account

Teva reports in 1st-qtr 2025 with key innovative medicines growing ~40%

home / authors / rishi-pimentel-gchem
Articles
Gaylord Chemical is Now gChem
How gChem (formerly Gaylord Chemicals) is embracing its rebrand that aligns with green chemistry, innovation, and regulatory excellence
Latest Updated Articles
Published: February 4th 2025 | Updated: March 3rd 2025
Advancing ADCs to the Next Level
Published: October 10th 2

Rishi Pimentel, gChem

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com
Norway-based Circio Holding (Circio) plans to present new and strengthened circular RNA in-vivo data in a poster exhibit at the 2025 American Society of Gene and Cell Therapy (ASGCT) meeting in New

Circio to Present Poster on CircRNA In Vivo Data at ASGCT 2025

The traditional boundaries between consumer wellness and healthcare are rapidly dissolving. This convergence is creating unprecedented opportunities for innovation, while fundamentally changing how individuals engage with their health.
Spanning multiple sectors, from pharmaceuticals to retail, this transformation has far-reaching implications for b

The Convergence of Consumer Wellness and Healthcare

Bristol Myers Squibb has announced plans to invest $40 billion in the United States over the next five years, focusing on expanding its domestic research, development, and manufacturing capabilities.
The investment will be directed toward advancing U.S.-based research and development, building out domestic manufacturing infrastructure, and incorpor

Bristol Myers Squibb to invest $40B in US R&D and manufacturing

AGC Biologics entered a multiphase partnership with Novelty Nobility Inc., a clinical-stage biotech company based in South Korea.
Novelty Nobility develops innovative antibody drugs, including bispecific antibodies and antibody-drug conjugates (ADCs). The company is currently developing two clinical assets in the United States in immunology and onc

AGC Biologics & Novelty Nobility Partner for Cell Line Development

In March 2024, Amgen opened a 270,000 square-foot facility in New Albany, Ohio supporting its manufacturing network through the addition of assembly and final product packaging capabilities. The site, first touted in 2021, saw an investment of $365 million.
Slightly over a year later and the firm has announced plans to invest a further $900 million

Amgen ploughing $900m into Ohio production site

Labeling/Printing
Antares Vision Group Partners with Siempharma to Create Automatic Labeler for Cylindrical Containers
Antares Vision Group
The ETF-300 Labeling Machine offers precise, high-speed labeling for a wide variety of common pharmaceuticals containers.
Labeling/Printing
Robotic Labeling Cell with Market’s Smallest Fully Integrated Servo Gr

Labeling/Printing

Tuesday, May 06, 2025
BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced the launch of VivoSTART™ Cryopreserved GMP Leukopaks. The GMP-compliant leukopaks ensure the quality, safety, and traceability of cellular starting material to support cell and gene therapy (CGT) platform p